Onco360, a leading independent specialty pharmacy, has been selected as a national pharmacy partner for VEPPANU (vepdegestrant), a new FDA-approved treatment for advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation. VEPPANU works by degrading estrogen receptors in cancer cells and showed significant improvement in progression-free survival in a Phase 3 trial compared to fulvestrant. This partnership aims to improve patient access to this innovative therapy while providing personalized clinical support. Onco360 is part of PharMerica Corporation and serves oncology patients nationwide through its accredited pharmacy network.
Keppel Ltd. is set to release its Q2 earnings with expected EPS of $0.33 and revenue of $2.06 billion. The company recently formed a $1.5 billion partnership with Apollo-managed funds to create a new offshore energy asset fund, highlighting its strat...
A broad sell-off on Wall Street pushed the S&P 500 to four-week lows, heavily impacting leveraged ETFs and individual stocks. Leveraged ETFs like the Daily Target 2X Long LMND ETF fell sharply by over 48%, reflecting their amplified risk and volatili...
The YMCA of Northern Alberta and the Edmonton Oilers Community Foundation are partnering for the second year to offer a summer day camp experience at the Fan Park in downtown Edmonton. This year, the program has doubled its reach to nearly 1500 child...
Pearson announced the winners of the 2026 Microsoft Office Specialist World Championship held in Anaheim, California, featuring 135 finalists from 36 countries. The competition recognizes students aged 13-22 who excel in Microsoft Word, Excel, and Po...
Raymond James upgraded Flex's price target from $150 to $170 following the company's strong fiscal Q1 2027 results, which included $7.93 billion in revenue and $1.00 adjusted earnings per share, beating estimates. Flex's Cloud and Power Infrastructur...
